Study guide

10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations

Key Takeaways Explain This Topic AI

Media-fill testing replaces every component of the most challenging compounding procedure with soybean-casein digest medium to show that the operator can compound without contamination.

The simulation must capture risk factors such as process length and fatigue, the number of transfers and manipulations, and the number of people in the room.

Commercial medium needs a supplier COA confirming growth promotion; medium made in-house needs growth promotion testing for each batch per USP <71>.

Units are incubated at least 7 days at 20-25 °C and at least 7 days at 30-35 °C, in the order the SOP specifies, and a single turbid unit fails the test.

The aseptic manipulation competency also includes a gloved fingertip sample inside the PEC (> 3 CFU) and a surface sample of the direct compounding area. Failing any part fails the competency, which repeats every 6 months (Category 1 and 2) or every 3 months (Category 3).

Last updated: September 2026

The Core Philosophy of Aseptic Process Simulation

Aseptic process simulation, commonly designated as media-fill testing , is the gold standard empirical evaluation of an operator's aseptic compounding competency. While written testing assesses knowledge and gloved fingertip sampling evaluates gowning, the media-fill simulation tests the entire sterile compounding process under real-world operational conditions.

In a media-fill test, sterile microbiological growth medium is substituted in place of active drug products and pharmaceutical diluents. Compounding personnel manipulate the sterile broth using the exact syringes, needles, transfer sets, automated pumps, filters, and container-closure systems used in routine compounding. If viable microorganisms are introduced at any point during the process, the incubated nutrient broth supports microbial replication, resulting in visible turbidity (cloudiness).

Regulatory Mandates & Cadence under USP <797> (2023)

USP <797> mandates that every individual who compounds sterile preparations must successfully complete media-fill testing according to the following strict timeline:

Initial Qualification : Prior to compounding sterile preparations independently.

Category 1 & Category 2 Compounding : At least every 6 months (semi-annually) .

Category 3 Compounding : At least every 3 months (quarterly) .

Supervisors who do not compound : Annually, simulating the hardest procedures of the people they oversee.

The media fill is one of three parts of the aseptic manipulation competency . Right after the media fill, a gloved fingertip and thumb sample is taken inside the ISO Class 5 PEC (action level > 3 CFU ), and the direct compounding area is surface sampled. A failure in any of the three is an overall failure.

  • Growth Medium Specifications & Growth Promotion Testing
  • Medium Selection

The compendial growth medium mandated for aseptic process simulations is Soybean-Casein Digest Medium (SCDM) , commonly known as Tryptic Soy Broth (TSB) . TSB provides rich enzymatic digests of casein and soybean meal, dextrose, and sodium chloride, creating a highly supportive environment for the rapid recovery of:

  • Aerobic and facultative anaerobic vegetative bacteria (e.g., Staphylococcus aureus , Pseudomonas aeruginosa )
  • Spore-forming bacteria (e.g., Bacillus subtilis )
  • Fungi and environmental molds (e.g., Aspergillus brasiliensis )
  • Yeasts (e.g., Candida albicans )
  • Growth Promotion Testing (GPT) & Certificate of Analysis (CoA)

Compounding facilities must ensure that the broth utilized is capable of sustaining low-level microbial growth:

Commercial Pre-Sterilized Broth : Each manufacturer lot must be accompanied by a manufacturer Certificate of Analysis (CoA) confirming sterility and demonstrating compliance with USP <71> Growth Promotion Testing.

Non-Commercial or Powdered Media : If broth is reconstituted and sterilized in-house, the facility must perform USP <71> growth promotion challenges, inoculating sample containers with < 100 CFU < 100\text{ CFU} < 100 CFU of compendial challenge organisms to verify growth recovery.

"Worst-Case" Simulation Design Principles

Under USP <797>, media-fill protocols must not be simplified, low-stress demonstrations. The simulation must represent the most challenging, complex, and stressful compounding conditions encountered during routine operations.

Elements of a Robust Simulation Design

Longest Operating Duration : The media-fill must equal or exceed the longest continuous compounding session performed by the employee (e.g., simulating a 2- to 4-hour batch compounding session).

Operator Fatigue Factor : Simulations should be scheduled at the end of a demanding compounding shift when physical fatigue, cognitive distraction, and ergonomic degradation are at their peak.

Maximum Number of Transfers & Manipulations : Incorporate multiple sequential syringe transfers, needle punctures through rubber stoppers, ampule breakages, stopcock manipulations, and transfer tubing attachments.

Broadest Range of Container Closures : Utilize both the smallest containers handled by the facility (e.g., 1 mL to 2 mL glass ampules or ophthalmic droppers requiring fine motor dexterity) and large-volume parenterals (e.g., 1,000 mL IV infusion bags).

Complex Equipment & Automation : If the facility utilizes automated compounding devices (ACDs), repeater pumps, or sterilizing filtration assemblies, these exact mechanical interfaces must be integrated into the simulation.

  • Incubation Parameters & Optical Inspection Protocols
  • The Mandatory 14-Day Dual-Temperature Incubation Regimen

USP <797> (2023 Revision) establishes a mandatory 14-day total incubation period utilizing a specific two-temperature sequence designed to ensure the biological recovery of both bacterial and fungal contaminants:

Temperature Phase 1 : Incubate at 20 ∘ C to 25 ∘ C 20^\circ\text{C} \text{ to } 25^\circ\text{C} 2 0 ∘ C to 2 5 ∘ C for a minimum of 7 consecutive days .

Biological Rationale : Lower temperatures optimize the recovery and germination of slow-growing environmental molds, yeasts, and dermatophytic fungi.

Temperature Phase 2 : Incubate at 30 ∘ C to 35 ∘ C 30^\circ\text{C} \text{ to } 35^\circ\text{C} 3 0 ∘ C to 3 5 ∘ C for a minimum of 7 consecutive days .

Biological Rationale : Higher temperatures optimize the metabolic replication of mesophilic human commensal and pathogenic bacteria.

Important

USP <797> permits the temperature phases to be executed in either order ( 20 ∘ C to 25 ∘ C 20^\circ\text{C} \text{ to } 25^\circ\text{C} 2 0 ∘ C to 2 5 ∘ C first, followed by 30 ∘ C to 35 ∘ C 30^\circ\text{C} \text{ to } 35^\circ\text{C} 3 0 ∘ C to 3 5 ∘ C , or vice versa). However, the container must complete the full 14 days of total incubation ; neither incubation phase can be shortened!

Optical Inspection Protocols

Inspection Environment : Media-fill units must be visually examined periodically throughout incubation (e.g., on days 3, 7, 10, and 14) and at the completion of the 14 days.

Background Lighting : Units must be inspected against contrasting black and white backgrounds under high-intensity illumination to detect discrete micro-colonies, delicate fungal hyphae, or faint cloudiness.

Pass/Fail Acceptance Standard : Zero Tolerance (0 CFU / Zero Turbidity) !

Pass : 100% of filled units remain crystal clear.

Fail : Even a single container exhibiting turbidity, haziness, surface pellicle, or particulate sediment constitutes an immediate, catastrophic failure of the entire simulation.

Failure Investigations, Root Cause Analysis & CAPA Workflows

A media-fill failure demonstrates that microbial contamination penetrated the preparation during compounding, presenting an immediate, life-threatening danger to patients. An immediate quality assurance and regulatory protocol must be initiated:

1. Immediate Operational Containment

Suspension of Compounding Privileges : The operator who failed the media-fill is immediately barred from compounding any sterile preparations.

Product Risk Review : Many facilities review CSPs made by that operator since the last passing test, quarantine any still in inventory, and decide under the recall SOP whether dispensed CSPs within their BUD need action.

2. Root Cause Analysis (RCA) & Microbial Speciation

Organism Identification : Identifying the contaminant, ideally at least to genus, for example by MALDI-TOF or sequencing, points to its source. It is strongly advised for a failure investigation.

Gram-Positive Cocci ( Staphylococcus epidermidis , Micrococcus ): Points directly to touch contamination, shedding of skin squames, or glove/gown breach.

Spore-Forming Rods ( Bacillus species): Implicates airborne dust intrusion, HVAC HEPA failure, or lack of sporicidal disinfectant application.

Gram-Negative Rods ( Pseudomonas , Burkholderia , Serratia ): Implicates water splashes from ante-room handwashing sinks, wet gloves, or moisture condensation.

Facility Engineering Audit : Certifier logs, HEPA filter face velocities, cleanroom smoke pattern studies, and room pressure differentials must be audited to rule out physical facility failure.

3. Corrective and Preventive Action (CAPA) & Re-qualification

The operator must undergo comprehensive, documented retraining in aseptic manipulations, cleanroom behavior, and DCA airflow maintenance.

Re-qualification Mandate : The results and corrective actions are documented. The operator must pass a new, complete aseptic manipulation competency (all units clear, a GFT of 3 CFU or less, and a passing surface sample) before compounding again.